Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Retinoblastoma 2Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous-Cell Lung Cancer 1Sjogren's Syndrome 1Scleroderma, Systemic 1Retinal Neoplasms 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Resectable Non-small Cell Lung Cancer 1Resectable Lung Non-Small Cell Carcinoma 1Recurrence 1Psoriasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Cancer Recurrent 1Oropharyngeal Neoplasms 1Nonsquamous Non-small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Sclerosis 1Melanoma 1Lymphatic Metastasis 1

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2sintilimab 1osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Platinum Compounds 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Resectable Non-small Cell Lung Cancer × Platinum Compounds × Clear all
NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Tang-Du Hospital

Phase 3 Not yet recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡